Last reviewed · How we verify
Thymoglobulin + Everolimus
Thymoglobulin is an anti-CD3 monoclonal antibody that depletes T cells, while Everolimus is an mTOR inhibitor that suppresses cell proliferation.
Thymoglobulin is an anti-CD3 monoclonal antibody that depletes T cells, while Everolimus is an mTOR inhibitor that suppresses cell proliferation. Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | Thymoglobulin + Everolimus |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | Immunosuppressant |
| Target | CD3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Thymoglobulin works by binding to CD3 receptors on T cells, leading to their depletion and immunosuppression. Everolimus, on the other hand, inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth and proliferation. By combining these two mechanisms, Thymoglobulin + Everolimus can effectively suppress the immune system and prevent organ rejection.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
- Infections
Key clinical trials
- EVEROLD LONG TERM FOLLOW-UP
- Treg Modulation With CD28 and IL-6 Receptor Antagonists (PHASE1, PHASE2)
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response (PHASE4)
- Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients (NA)
- Comparing Everolimus and Sirolimus in Renal Transplant Recipients (NA)
- Regimen Optimization Study (PHASE2)
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) (PHASE4)
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymoglobulin + Everolimus CI brief — competitive landscape report
- Thymoglobulin + Everolimus updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI